#USA #Class Action #Securities Laws #Eastchester #Immutep Limited

Class Action Lawsuit Against Immutep Limited

Investors and shareholders of Immutep Limited, a biopharmaceutical company traded on NASDAQ under the ticker IMMP, have come together to hold the Company accountable over serious allegations of securities law violations. The DJS Law Group has officially announced that it is spearheading a class action lawsuit against Immutep for breaching sections of the Securities Exchange Act of 1934.

Legal Background

The lawsuit is primarily rooted in allegations that Immutep provided false and misleading information to the investors. Between March 24, 2025, and March 12, 2026, shareholder confidence was allegedly undermined as the Company made optimistic claims regarding its TACTI-004 trial of the drug eftilagimod alfa (also known as efti). Immutep officials had touted the trial’s progress as 'strong', despite knowing that the results would likely fail to meet the essential efficacy endpoints.

The legal filings assert that these declarations were not only misleading but materially false, leading to significant financial losses for investors who purchased shares during the given class period.

What This Means for Shareholders

For shareholders affected during this period, the DJS Law Group encourages you to reach out to discuss your rights and explore potential avenues for recovery. It is crucial to note that you do not need to be appointed as the lead plaintiff in order to recuperate losses from this situation. The deadline for filing claims has been set for July 6, 2026.

Potential Impacts of the Lawsuit

This lawsuit comes as a critical juncture for Immutep and could have ongoing repercussions on its stock performance and business operations. The outcome of the case may not only affect current shareholders but also impact potential investors' perceptions of the Company. Legal experts emphasize the importance of transparency and accountability in promoting trust within the financial markets, especially regarding the information companies provide about clinical trials and drug efficacy.

About DJS Law Group

The DJS Law Group specializes in securities-related litigation and is committed to advocating for investor rights. The firm is known for robust representation in class actions and corporate governance litigations, providing clients with expert guidance to navigate complex legal landscapes. Their clientele includes major hedge funds and alternative asset managers, underscoring their expertise in handling significant securities claims.

By reaching out to DJS Law Group for representation, shareholders are taking an essential step towards securing their investments and demanding justice from misleading corporate practices.

How to Get Involved

If you are a shareholder who faced financial challenges as a result of Immutep's alleged misconduct, we urge you to act promptly. Gather your documentation concerning share purchases within the specified timeframe and contact the DJS Law Group. With your participation, you can join other shareholders in seeking justice and recovery from the potential damages.

For further information or to initiate your claim, please contact:

• - David J. Schwartz
• - DJS Law Group
• - Address: 274 White Plains Road, Suite 1, Eastchester, NY 10709
• - Phone: 914-206-9742
• - Email: [email protected]